2.3
2022

Dupilumab to induce tolerance to SLIT-Melocotón®

Show more: Authors information and Publication history
Authors Information

General Universitary Hospital Reina Sofía, Murcia, Spain

History

Published: 13 January 2023
Accepted: 09 Januray 2023
Received: 28 October 2022

SUMMARY

Food allergy is an increasing problem for population, and treatments inducing tolerance using sublingual immunotherapy is currently under study. Our aim as allergists is to achieve tolerance to sublingual allergen specific immunotherapy with sublingual immunotherapy (SLIT-peach). We present a case report consisting of a 40-year-old woman with anaphylactic reactions after eating fruit and other plant-foods due to sensitization to non specific lipid transfer proteins (nsLTP). Her diagnose was LTP-syndrome. This protein is the main pannallergen in our area and causes crossed reaction to multipleplant foods. The principal allergen in this syndrome is rPru p3, present in peach and most vegetables, fruits, nuts and grains. Serum specific IgE levels were performed using microarrays and positive for seven nsLTPs: rAra h9,rCor a8, nJug r3, rPru p3, rTri a 14, nArt v3 and rPla a3. Immediate reactionto SLIT in the fourth month of maintenance-dose led us to interrupt prup3 immunotherapy. Immediate reaction to omalizumab in the fourth dose in hospital consisting in anaphylaxis prompted us to switch to dupilumab. After four months with this monoclonal antibody, we reintroduced sublingual immunotherapy with pru p3 SLIT-peach® achieving maintenance dose of four drops a day with no clinical reactions. SLIT-peach® in our patient is crucialfor her due to her restricted diet, the severity of reactions and lack of quality of life measured by Europevall questionary. There are no cases reported for dupilumab in this use

KEY WORDS
Dupilumab; LTP-syndrome; food allergy; Pru p3; SLIT-melocotón®.

Table of Content: Vol. 56 (No. 3) 2024 May

European Annals of Allergy and Clinical Immunology ISSN 1764-1489 | © 2024